Oakworth Capital, Inc. Biogen Inc. Transaction History

Oakworth Capital, Inc.

$1.44 Billion
Q3 2024

A detailed history of Oakworth Capital, Inc. transactions in Biogen Inc. stock. As of the latest transaction made, Oakworth Capital, Inc. holds 659 shares of BIIB stock, worth $98,850. This represents 0.01% of its overall portfolio holdings.

Number of Shares

659

Previous 659 -0.0%

Holding current value

$98,850

Previous $152,000 16.45%

% of portfolio

0.01%

Previous 0.01%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 05, 2022	BUY	$187.54 - $223.02 $123,588 - $146,970	659 New	659 $134,000
Q2 2021 Jul 20, 2021	SELL	$259.0 - $414.71 $198,135 - $317,253	-765 Closed	0 $0
Q3 2020 Nov 09, 2020	SELL	$264.77 - $305.71 $794 - $917	-3 Reduced 0.39%	765 $217,000
Q2 2020 Aug 11, 2020	SELL	$258.66 - $342.55 $76,304 - $101,052	-295 Reduced 27.75%	768 $205,000
Q1 2020 May 07, 2020	SELL	$268.85 - $341.04 $13,980 - $17,734	-52 Reduced 4.66%	1,063 $336,000
Q4 2019 Jan 31, 2020	SELL	$220.06 - $304.07 $8,142 - $11,250	-37 Reduced 3.21%	1,115 $326,000
Q3 2019 Nov 13, 2019	SELL	$217.44 - $243.88 $27,832 - $31,216	-128 Reduced 10.0%	1,152 $268,000
Q2 2019 Aug 02, 2019	BUY	$219.29 - $241.72 $28,726 - $31,665	131 Added 11.4%	1,280 $299,000
Q1 2019 May 06, 2019	SELL	$216.71 - $338.96 $3,250 - $5,084	-15 Reduced 1.29%	1,149 $272,000
Q4 2018 Feb 13, 2019	BUY	$278.5 - $352.75 $198,570 - $251,510	713 Added 158.09%	1,164 $350,000
Q3 2018 Oct 25, 2018	BUY	$293.51 - $383.83 $132,373 - $173,107	451 New	451 $159,000
Q4 2017 Jan 22, 2018	SELL	$307.64 - $344.58 $2,768 - $3,101	-9 Closed	0 $0
Q3 2017 Nov 08, 2017	BUY	$281.15 - $329.69 $2,530 - $2,967	9	9 $3,000

Others Institutions Holding BIIB

# of Institutions

1,037

Shares Held

126M

Call Options Held

1.13M

Put Options Held

1.43M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.6B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Oakworth Capital, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Oakworth Capital, Inc. with notifications on news.

Account

Oakworth Capital, Inc. Biogen Inc. Transaction History